New Recruiting Trial: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
WHY IT MATTERS
This trial offers eligible patients with advanced unresectable hepatocellular carcinoma access to a novel three-drug combination that may provide a new treatment option beyond current standard therapies.
Researchers are testing a new combination of three drugs (RBS2418, tremelimumab, and durvalumab) to treat advanced hepatocellular carcinoma, a type of liver cancer that cannot be surgically removed. This is an early-stage clinical trial (Phase 2) that is currently accepting patients. The study aims to see if combining these drugs works better than existing treatments.
NCT ID: NCT07175441 Title: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma Status: RECRUITING Phase: PHASE2 Sponsor: Riboscience, LLC. Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07175441 Source: UniteRare clinical trials database
ASK YOUR DOCTOR
If you have advanced unresectable hepatocellular carcinoma, ask your oncologist whether you might be eligible for this trial and how to learn more about enrollment at NCT07175441.